![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy and Safety of Co-Formulated Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Chronic HCV Genotype 4 Infection Without Cirrhosis and With Compensated Cirrhosis in Egypt (AGATE-II)
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco, CA
Gamal Esmat1, Wahid Doss2, Roula B Qaqish3, Imam Waked4, Gamal Shiha5, Ayman Yosry2, Mohamed Hassany2, Jennifer King3, Carolyn Setze3, Rebecca Redman3, Niloufar Mobashery3
1Cairo University, Cairo, Egypt; 2National Hepatology & Tropical Medicine Research Insti tute, Cairo, Egypt; 3AbbVie Inc., North Chicago, Illinois, United States; 4National Liver Institute, Menoufiya, Egypt; 5Egyptian Liver Research Institute And Hospital (ELRIAH), Dakahliah, Egypt
![AASLD1.gif](../images/111815/111815-2/AASLD1.gif)
![AASLD2.gif](../images/111815/111815-2/AASLD2.gif)
![AASLD3.gif](../images/111815/111815-2/AASLD3.gif)
![AASLD4.gif](../images/111815/111815-2/AASLD4.gif)
![AASLD5.gif](../images/111815/111815-2/AASLD5.gif)
![AASLD6.gif](../images/111815/111815-2/AASLD6.gif)
![AASLD7.gif](../images/111815/111815-2/AASLD7.gif)
![AASLD8.gif](../images/111815/111815-2/AASLD8.gif)
![AASLD9.gif](../images/111815/111815-2/AASLD9.gif)
![AASLD10.gif](../images/111815/111815-2/AASLD10.gif)
![AASLD11.gif](../images/111815/111815-2/AASLD11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|